Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa News Guide.
Press releases published on July 22, 2025
Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
GlobeNewswire
·
July 22, 2025
WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) …
Headwater Gold and OceanaGold Sign Letter of Intent to Explore Three Projects in Nevada
GlobeNewswire
·
July 22, 2025
VANCOUVER, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) -- Headwater Gold Inc. (CSE: HWG, OTCQB: HWAUF) (the "Company" or "Headwater") is pleased to announce it has signed a non-binding Letter of Intent (“LOI”) with a subsidiary of OceanaGold …
Titan Mining Closes Landmark US$15.8M Credit Agreement with US EXIM
GlobeNewswire
·
July 22, 2025
GOUVERNEUR, New York and VANCOUVER, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) -- Titan Mining Corporation (TSX: TI; OTCQB: TIMCF) (“Titan” or the “Company”) is pleased to announce that its wholly owned subsidiary, Empire State Mines, LLC (“ESM”), …
MEXC Launches Stock Futures, Leading a 0 Fee, Top-Tier Liquidity Trading Revolution
GlobeNewswire
·
July 22, 2025
VICTORIA, Seychelles, July 22, 2025 (GLOBE NEWSWIRE) -- Global crypto exchange MEXC has officially launched its new Stock Futures product, featuring 0 trading fees, 0 funding fees, deep global liquidity, and a streamlined user experience. This launch marks …
Telix Reports $204M Revenue, Up 63% YOY
GlobeNewswire
·
July 22, 2025
MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All …
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+
GlobeNewswire
·
July 22, 2025
SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety Overall response rate for iSCIB1+ was 69% for target HLA type patients, representing 80% of total patients - greatly …
Aura Announces S&P Global Upgrades Outlook to Positive B+ Rating on Larger Scale and Financial Performance
GlobeNewswire
·
July 22, 2025
ROAD TOWN, British Virgin Islands, July 21, 2025 (GLOBE NEWSWIRE) -- Aura Minerals Inc. (Nasdaq: AUGO) (TSX: ORA) (B3: AURA33) (“Aura” or the “Company”) today announced that S…